Apimeds Pharmaceuticals US, Inc (APUS:NYSEMKT) closed at $2.89 on October 23, 2026, down 8.54% on the day. The stock trades 95.2% below its 52-week high of $59.70 and 91.4% above its 52-week low of $1.51. Over the past year, it lost 85.4%. Apimeds Pharmaceuticals US, Inc is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, APUS closed higher on 93 days (37%). Its best day was September 24, 2026 (+114.85%) and its worst was May 6, 2026 (-35.00%). The stock moved 10% or more in a single session 66 times. It opened at least 5% above the previous day's high 9 times.
Apimeds Pharmaceuticals US is a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects. Apimeds is currently developing Apitox as a potential osteoarthritis treatment for patients with knee pain who failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. Apitoxin has been used in the South Korea to treat the reduction of pain associated with OA since 2003 and now we will be pursuing a second Phase III trial to meet agreed upon FDA standards. Upon the successful completion of our Phase III trial demonstrating therapeutic effect and extended safety data for the use of Apitox to treat pain and mobility in patients with knee OA, we intend to submit a Biologics License Application for Apitox.
Find more stocks like APUS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.